Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
Holders of 5% or more of ERAS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Erasca, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 5.70%16.1M shares | −1.50 ppfrom 7.20% | Aug 14, 20252 filings | Feb 17, 2026 | SEC |
| Paradigm Biocapital Advisors LP | 13G | 5.30%15.2M shares | New | Jan 14, 20261 filing | Jan 14, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.30%15.0M shares | −2.70 ppfrom 8.00% | May 15, 20252 filings | Aug 14, 2025 | SEC |
| Suvretta Capital Management, LLC | 13G | 5.10%14.5M shares | +0.70 ppfrom 4.40% | Feb 13, 20252 filings | Aug 13, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Erasca, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 202610:28 AM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 5.70%16.1M shares | −1.50 ppfrom 7.20% | Dec 31, 2025 | SEC |
| Jan 14, 20264:30 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G | 5.30%15.2M shares | New | Jan 7, 2026 | SEC |
| Nov 14, 202512:59 PM ET | Logos Global Management LPand 2 others | 13G/A | 4.80%13.6M shares | −0.50 ppfrom 5.30%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20254:56 PM ET | Logos Global Management LPand 2 others | 13G | 5.30%15.1M shares | New | Jun 30, 2025 | SEC |
| Aug 14, 20251:10 PM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 5.30%15.0M shares | −2.70 ppfrom 8.00% | Jun 30, 2025 | SEC |
| Aug 14, 202512:12 PM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 7.20%20.3M shares | – | Jun 30, 2025 | SEC |
| Aug 13, 20258:14 PM ET | Suvretta Capital Management, LLCand 2 others | 13G | 5.10%14.5M shares | +0.70 ppfrom 4.40% | Jun 30, 2025 | SEC |
| May 15, 20259:44 AM ET | Frazier Life Sciences Public Fund, L.P.and 16 others | 13G/A | 8.00%22.6M shares | – | Mar 31, 2025 | SEC |
| Feb 13, 20258:09 PM ET | Suvretta Capital Management, LLCand 2 others | 13G/A | 4.40%12.3M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 12, 20255:02 PM ET | Novartis Pharma AGand 1 other | 13G/A | 4.40%12.3M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Erasca, Inc. shares.
No Form 144 notices for Erasca, Inc. are on file.